Iontophoresis-driven microneedle patch for the active transdermal delivery of vaccine macromolecules.
Electrical and electronic engineering
Electronic properties and materials
Journal
Microsystems & nanoengineering
ISSN: 2055-7434
Titre abrégé: Microsyst Nanoeng
Pays: England
ID NLM: 101695458
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
11
2022
revised:
07
02
2023
accepted:
17
02
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
COVID-19 has seriously threatened public health, and transdermal vaccination is an effective way to prevent pathogen infection. Microneedles (MNs) can damage the stratum corneum to allow passive diffusion of vaccine macromolecules, but the delivery efficiency is low, while iontophoresis can actively promote transdermal delivery but fails to transport vaccine macromolecules due to the barrier of the stratum corneum. Herein, we developed a wearable iontophoresis-driven MN patch and its iontophoresis-driven device for active and efficient transdermal vaccine macromolecule delivery. Polyacrylamide/chitosan hydrogels with good biocompatibility, excellent conductivity, high elasticity, and a large loading capacity were prepared as the key component for vaccine storage and active iontophoresis. The transdermal vaccine delivery strategy of the iontophoresis-driven MN patch is "press and poke, iontophoresis-driven delivery, and immune response". We demonstrated that the synergistic effect of MN puncture and iontophoresis significantly promoted transdermal vaccine delivery efficiency. In vitro experiments showed that the amount of ovalbumin delivered transdermally using the iontophoresis-driven MN patch could be controlled by the iontophoresis current. In vivo immunization studies in BALB/c mice demonstrated that transdermal inoculation of ovalbumin using an iontophoresis-driven MN patch induced an effective immune response that was even stronger than that of traditional intramuscular injection. Moreover, there was little concern about the biosafety of the iontophoresis-driven MN patch. This delivery system has a low cost, is user-friendly, and displays active delivery, showing great potential for vaccine self-administration at home.
Identifiants
pubmed: 36987502
doi: 10.1038/s41378-023-00515-1
pii: 515
pmc: PMC10040928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare no competing interests.
Références
J Control Release. 2017 Nov 28;266:109-118
pubmed: 28943194
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
Arch Pharm Res. 2017 Nov;40(11):1238-1248
pubmed: 29027637
Dermatol Surg. 2021 Sep 1;47(9):1249-1254
pubmed: 34448760
J Mater Chem B. 2020 Jan 14;8(2):216-225
pubmed: 31803892
Sci Pharm. 2012;80(1):1-28
pubmed: 22396901
Int J Pharm. 2020 Aug 30;586:119584
pubmed: 32603836
Sensors (Basel). 2016 Sep 20;16(9):
pubmed: 27657072
AAPS PharmSciTech. 2019 Jul 22;20(7):257
pubmed: 31332640
Int J Pharm. 2021 May 15;601:120582
pubmed: 33872711
SAGE Open Nurs. 2018 Mar 14;4:2377960818759442
pubmed: 33415191
Anal Chem. 2020 Jan 21;92(2):2291-2300
pubmed: 31874029
J Pharm Innov. 2021;16(3):558-565
pubmed: 32837607
Nat Commun. 2021 Jan 28;12(1):658
pubmed: 33510169
Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):
pubmed: 34551974
Nat Biotechnol. 2008 Nov;26(11):1261-8
pubmed: 18997767
Drug Deliv. 2018 Nov;25(1):1728-1739
pubmed: 30182757
Int J Pharm. 2021 Nov 20;609:121092
pubmed: 34530098
Drug Deliv. 2016;23(2):564-78
pubmed: 25006687
J Am Chem Soc. 2013 Jul 17;135(28):10557-65
pubmed: 23795959
Adv Drug Deliv Rev. 2021 Dec;179:113919
pubmed: 34375682
Biofabrication. 2017 Jan 10;9(1):015010
pubmed: 28071597
J Control Release. 2020 Jul 10;323:323-332
pubmed: 32360305
J Control Release. 2020 Jan 10;317:336-346
pubmed: 31756393
Int J Pharm. 2020 Nov 15;589:119853
pubmed: 32898633
Angew Chem Int Ed Engl. 2020 Jul 13;59(29):12154-12161
pubmed: 32324959
Drug Deliv Transl Res. 2022 Jan;12(1):15-26
pubmed: 33486687
J Control Release. 2012 Jul 20;161(2):645-55
pubmed: 22342643
ACS Appl Mater Interfaces. 2018 Oct 24;10(42):36218-36228
pubmed: 30251533
Eur J Pharm Biopharm. 2005 Jul;60(2):179-91
pubmed: 15939232
J Emerg Nurs. 2019 Sep;45(5):502-511
pubmed: 31257044
Adv Mater. 2020 Jan;32(1):e1905740
pubmed: 31682039
Int J Mol Sci. 2018 Nov 19;19(11):
pubmed: 30463211
Signal Transduct Target Ther. 2021 Mar 8;6(1):114
pubmed: 33686059
Hum Vaccin Immunother. 2021 Jan 2;17(1):316-327
pubmed: 32667239
Adv Drug Deliv Rev. 2020 Jan 1;153:2-17
pubmed: 32339593
Vaccine. 2016 Dec 20;34(52):6707-6714
pubmed: 27773475
Vaccines (Basel). 2020 Sep 16;8(3):
pubmed: 32947966
Int J Mol Sci. 2018 Jul 29;19(8):
pubmed: 30060611
J Control Release. 2019 Jan 28;294:268-278
pubmed: 30572036
Res Pharm Sci. 2015 Jan-Feb;10(1):1-16
pubmed: 26430453
Langmuir. 2010 Aug 17;26(16):13086-96
pubmed: 20000620
Acta Biomater. 2021 Feb;121:349-358
pubmed: 33340733
ACS Appl Mater Interfaces. 2020 Jul 22;12(29):32259-32269
pubmed: 32406239